ForPatients
by Roche

Hemophilia A

Study of Emicizumab Prophylaxis in Participants With Hemophilia A and Inhibitors Undergoing Minor Surgical Procedures

Trial Status	Trial Runs In	Trial Identifier
Terminated	1 Countries	NCT03361137 ML39791

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This Phase IV, multicenter study will evaluate whether participants with Hemophilia A (PwHA) with or without inhibitors receiving emicizumab prophylaxis can safely undergo minor surgical procedures without additional prophylactic bypassing agents (BPA; for participants with inhibitors) or factor VIII (FVIII; for participants without inhibitors).

Genentech, Inc.
Sponsor

Phase 4
Phase

NCT03361137 ML39791
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	All	No

© 2022 F. Hoffmann-La Roche Ltd